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Abstract
Background: We compared mortality by cause of death in HIV-infected adults in the era of combined antiretroviral
therapy with mortality in the general population in the same age and sex groups.
Methods: Mortality by cause of death was analyzed for the period 1999-2006 in the cohort of persons aged 20-59
years diagnosed with HIV infection and residing in Navarre (Spain). This was compared with mortality from the
same causes in the general population of the same age and sex using standardized mortality ratios (SMR).
Results: There were 210 deaths among 1145 persons diagnosed with HIV (29.5 per 1000 person-years). About 50%
of these deaths were from AIDS. Persons diagnosed with HIV infection had exceeded all-cause mortality (SMR 14.0,
95% CI 12.2 to 16.1) and non-AIDS mortality (SMR 6.9, 5.7 to 8.5). The analysis showed excess mortality from
hepatic disease (SMR 69.0, 48.1 to 78.6), drug overdose or addiction (SMR 46.0, 29.2 to 69.0), suicide (SMR 9.6, 3.8 to
19.7), cancer (SMR 3.2, 1.8 to 5.1) and cardiovascular disease (SMR 3.1, 1.3 to 6.1). Mortality in HIV-infected
intravenous drug users did not change significantly between the periods 1999-2002 and 2003-2006, but it declined
by 56% in non-injecting drug users (P = 0.007).
Conclusions: Persons with HIV infection continue to have considerable excess mortality despite the availability of
effective antiretroviral treatments. However, excess mortality in the HIV patients has declined since these
treatments were introduced, especially in persons without a history of intravenous drug use.
Background
The expansion of combined antiretroviral treatments in
the developed countries has been followed by substantial
reductions in the incidence of AIDS-defining conditions
and mortality among HIV-infected persons [1,2]. With
these treatments and in the absence of other risk fac-
tors, mortality in HIV-infected persons approaches that
of similarly aged persons with chronic diseases and is
becoming closer to mortality in the general population
of a similar age [3-5].
Mortality in HIV-infected persons depends on the
duration of infection, age at the time of seroconversion
and the effectiveness of the antiretroviral treatment [6];
this, in turn, depends on when treatment was started,
whether previous treatment responses have been subop-
timal, and the presence of coinfections [7,8]. Combined
antiretroviral treatments were introduced when many
countries had a considerable number of HIV- infection
with long evolution of the disease and other comorbid-
ities. These factors have meant that the real impact of
these treatments on mortality has been less than what
could be reached under ideal conditions. Various studies
have related these treatments with substantial reductions
in mortality from AIDS-defining conditions, but mortal-
ity from other causes may decrease to a lesser extent or
may remain stable [8-10].
Many studies evaluating the effect of combined antire-
troviral treatments on mortality in HIV-infected persons
have been done in cohorts of patients during clinical fol-
low-up [11], or who were being followed up regularly in
HIV clinics [3,4,12,13], or who were beginning to
receive combined antiretroviral treatment [14,15]. How-
ever, such studies may under-represent persons who
died before the beginning medical follow-up, do not
have regular check-ups, are difficult to recruit, or died
from causes unrelated to HIV infection. Accordingly,
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optimistic and not representative of the entire popula-
tion of people living with HIV.
The objective of this study was to analyze total mortality
and mortality by cause of death in a population-based
cohort of adults diagnosed with HIV during a period of
wide availability of combined antiretroviral treatments and
to compare it with mortality in the general population of
the same age and sex and living in the same region.
Methods
This study analyzed the population-based cohort of per-
sons residing in the region of Navarre (approximately
600,000 inhabitants), Spain, with a diagnosis of HIV
infection confirmed by Western blot. The information
was obtained from the HIV epidemiological surveillance
system that was launched in Navarre in 1991. All HIV-
infected patients diagnosed by laboratories of the region
were incorporated retrospectively, followed by a contin-
uous active search of all new laboratory-confirmed cases
and patients attended in clinical centers [16,17]. Infor-
mation on AIDS diagnoses was completed by reviewing
the AIDS case register [16], and information on vital
status was completed by reviewing the regional mortality
records [18]. These data sources include AIDS diagnoses
and deaths among Navarre residents occurred both
within and outside the region that are reported at
national level. To rule out the possibility of undetected
HIV cases, AIDS diagnoses or deaths outside the region,
additional searches were made in the dataset of hospital
discharges, in the national AIDS registry, and in the
national death index of Spain [19] (Table 1). All indivi-
duals who maintained their residence in Navarre and
who were not shown as dead in any of these sources
were considered to be alive at the end of the follow-up.
Most HIV infections in Navarre have occurred in
intravenous drug users, although sexual transmission
has predominated in recent years. The entire population
of the region has easy and free access to medical care
and to the HIV test. Combined antiretroviral treatments
are free and have been available since 1996 in accor-
dance with internationally accepted treatment protocols
[17].
The present analysis was limited to persons aged
20-59 years with stable residency in Navarre during the
study period. The follow-up starting date was considered
to be the date when HIV infection was diagnosed, the
date when the person reached 20 years of age or 1 Janu-
ary 1999, whichever was latest. Follow-up of subjects
was ceased at death or on 31 December 2006 for those
who survived to that date. We calculated the mortality
rates by cause of death, taking the number of person-
years (PY) of follow-up as the denominator.
The reference population consisted of persons aged
20-59 years residing in Navarre according to the census
data at the beginning of each study year, minus the
number of person-years of follow-up corresponding to
persons diagnosed with HIV infection. Deaths in the
reference population were obtained from the regional
mortality registry, and the number of deaths occurred in
persons diagnosed with HIV were subtracted from it.
The primary cause of death according to the Interna-
tional Classification of Diseases 10th edition was also
obtained from this mortality registry [20].
The causes of death were grouped into the following
categories: AIDS or HIV infection (B20-B24, R75), hepa-
tic disease (B15-B19, B70, K73, K74, K769), non-AIDS
defining cancers (C00-D48), drug addiction and over-
dose (F11, F16, F18, F19, X41, X42, X44, X45), cardio-
vascular disease (I00-I99), suicide (X60-X84), and other
external causes (V01-Y89, excluding codes included in
the preceding categories). Death certificates were
reviewed from deaths coded as B20.3 and B23.8, and
when the cause of death was liver disease or cirrhosis it
was reclassified in the category of liver diseases rather
than AIDS [20]. Deaths from acute pulmonary edema or
other non-specific causes in parenteral drug users were
reviewed taking the forensic report into account.
Mortality in persons diagnosed with HIV infection was
compared with mortality in the rest of the population by
calculating standardized mortality ratios (SMR) adjusted
for sex and 5-year age groups; the 95% confidence inter-
vals were obtained by applying the Poisson distribution.
The analyses were stratified by sex and history of intra-
venous drug use to rule out the influence of such vari-
ables in the mortality comparisons.
Mortality in the HIV-infected cohort during the per-
iod of 1999-2002 was compared with that of during the
period of 2003-2006 using Cox regression models, with
age as the underlying time variable. Exit time was
defined as the date of death or the end of the period,
whichever came first.
Table 1 Information sources used
Sources of information Use
Epidemiological surveillance system
of cases diagnosed with HIV-
infection: active search of cases in
records of laboratories and clinicians
Main source of HIV-infected
cases
Hospital discharges database Complementary source for
quality control of HIV-infected
cases
Regional AIDS-register Main source of cases with AIDS-
defining conditions
National AIDS-register Complementary source for
quality control of AIDS cases
Regional mortality register Main source for deaths
National death index Complementary source for
quality control of deaths
Aldaz et al. BMC Public Health 2011, 11:300
http://www.biomedcentral.com/1471-2458/11/300
Page 2 of 8The c
2 test was used to compare proportions and
values of P < 0.05 were considered to be significant.
Results
Characteristics of the HIV-infected subjects who died
On 1 January 1999, there were 879 individuals aged 20-
59 years in follow-up in Navarre who had been diag-
nosed with HIV infection, and 266 new cases were
added by the end of 2006. Of all these cases, 68% were
men, 63% had a history of intravenous drug use, and
35% had a previous diagnosis of AIDS or were diag-
nosed with AIDS during follow-up. Between 1999 and
2006, there were 210 deaths among individuals in fol-
low-up (29.5 per 1000 person-years) with a higher rate
of deaths in men (34.2 per 1000 PY), in intravenous
drug users (33.5 per 1000 PY), and in persons previously
diagnosed with AIDS (67.1 vs. 15.2 per 1000 PY, P <
0.001). Over half of those included in the cohort had
been diagnosed with HIV infection at least 5 years
before, and mortality was higher in this group (Table 2).
50.5% of deaths were due to AIDS-defining conditions,
17.1% due to liver diseases, 11.0% due to drug overdose
or addiction, 8.1% due to non-AIDS-defining cancers,
3.8% due to cardiovascular disease and 3.3% due to
suicides.
The median time from HIV diagnosis to death was
11.4 years. About 5.2% (n = 11) of he deaths occurred
in the first 3 months after the HIV diagnosis. This per-
centage was higher in parenteral drug users (16.3% vs.
1.9%, P < 0.001). Ten of these deaths were from AIDS-
defining conditions and one from hepatic disease.
Comparison with the general population
Mortality among persons diagnosed with HIV was 14
times higher than mortality in the general population of
the same sex and age groups (SMR, 14.0; 95% CI, 12.2
to 16.1); after excluding deaths from AIDS, high mortal-
ity in individuals with HIV persisted and was 6.9 times
higher (5.7 to 8.5). Such high mortality in persons diag-
nosed with HIV was mainly from the liver disease (SMR
69.0, 48.1 to 78.6), drug overdose or addiction (SMR
46.0, 29.2 to 69.0) and suicide (SMR 9.6, 3.8 to 19.7)
and, in lesser measure, from non-AIDS defining cancers
(SMR 3.2, 1.8 to 5.1), cardiovascular disease (SMR 3.1,
Table 2 Characteristics of persons included in the cohort of HIV-infected subjects, and number and rate of deaths
according to these characteristics; Navarre, Spain, 1999-2006
HIV-infected subjects Deaths P-value
N % Person-years N Rate per 1000 person-years
Sex <0.001
Male 781 68 4734 162 34.2
Female 364 32 2379 48 20.2
Risk categories <0.001
Injecting drug users 721 63 4839 162 33.5
Homo-/bisexual men 85 7 478 5 10.5
Heterosexual 263 23 1328 34 25.6
Other/unknown 76 7 877 9 10.3
Country of origin 0.398
Spain 1024 89 6655 200 30.0
Other 121 11 458 10 21.8
AIDS-defining condition <0.001
Yes 402 35 1967 132 67.1
No 743 65 5146 78 15.2
Year of HIV diagnosis <0.001
1990 or before 307 27 1744 76 43.6
1991-1995 354 31 1779 75 42.2
1996-1999 242 21 1787 35 19.6
2000-2006 242 21 1802 24 13.3
Total 1145 100 7113 210 29.5
P value for comparison of rates within categories.
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Page 3 of 81.3 to 6.1) and other causes (SMR 5.1, 2.3 to 9.7). Excess
mortality in persons diagnosed with HIV was more pro-
nounced in those who had a history of intravenous drug
use (SMR 17.7, 15.2 to 20.8) than in those who did not
(SMR 8.2, 6.0 to 11.0). Among the former group, there
was notably increased mortality from causes other than
AIDS (SMR 9.6, 7.7 to 12.0); especially from liver dis-
ease (SMR 96.6, 65.2 to 138.1) and from drug overdose
or addiction (SMR 63.4, 40.2 to 95.1) (Table 3).
Among non-injecting drug users, mortality from
causes other than AIDS (SMR 2.7, 1.6 to 4.4) was still
higher than the general population but less than that
among the intravenous drug users. In non-injecting
drug users the increase in mortality was again primarily
due to liver diseases (SMR 28.4, 10.4 to 62.0) (Table 3).
Cox regression models were used to compare mortal-
ity in the cohort of HIV-infected persons between the
periods of 1999-2002 and of 2003-2006, adjusted for
sex, age, intravenous drug use and country of origin.
AIDS mortality in HIV-infected persons decreased by
37% (adjusted hazard ratio [HR] 0.63; 95% CI 0.42-0.95;
P = 0.026). Mortality in intravenous drug users
remained high with a non-statistically significant change
between the two periods (HR 0.85; 95% CI 0.60-1.19; P
= 0.336), whereas mortality in non-injecting drug users
decreased by 56% (HR 0.44; 95% CI 0.24-0.79; P =
0.007), with a 51% reduction in mortality caused by
AIDS (HR 0.49; 95% CI 0.24-1.02; P = 0.057) and 67%
reduction in mortality from causes other than AIDS
(HR 0.33; 95% CI 0.11-0.96; P = 0.041) (Table 4).
Discussion
Persons diagnosed with HIV infection had considerable
excess mortality in comparison with the general popula-
tion of the same age group and sex, despite wide avail-
ability of combined antiretroviral treatments. This
excess mortality was largely due to deaths from AIDS-
defining conditions, but other causes of death were also
important, such as drug overdose or addiction, hepatic
disease, non-AIDS-defining cancers, and cardiovascular
disease. Excess mortality associated with HIV infection
was observed in both men and women, and in persons
with and without a history of injecting drug use.
Numerous studies have reported substantial reduc-
tions in mortality in HIV-infected persons after the
introduction of combined antiretroviral treatments
[21,22], the same as we found in Navarre [9]. Nonethe-
less, mortality in this group is still 14 times higher than
in the general population after adjusting for sex and age
group. Some studies have found somewhat lower excess
mortality [23], but different results could be explained
by the epidemiological characteristics of those infected,
time of evolution of the infection, and whether or not
persons who are not receiving antiretroviral treatment
are included. Health authorities should be alert not only
to those causes with relative excess mortality, but also
to those that are responsible for the largest absolute
number of deaths.
In the era of combined antiretroviral treatments, mor-
tality among persons diagnosed with HIV has continued
to decline, mainly in those without a history of injecting
drug use [21], but is still a long way from reaching mor-
tality levels similar to those in the general population
[5].
We found that the weight of AIDS-defining diseases
has decreased in favor of other causes, although they
continue to be the leading cause of death in HIV-
infected persons [24]. Possible explanations for this
include delayed diagnosis of HIV infection, HIV-infected
subjects who refuse to receive antiretroviral treatment,
and low adherence to these treatments. Delayed diagno-
sis has been detected in 37% of cases of HIV-infection
diagnosed in Spain [25]. People who are unaware of
their infection probably have a higher risk of death than
diagnosed subjects, thus earlier diagnosis would reduce
the excess mortality. Some misclassification is also pos-
sible since doctors may be prone to certify deaths in
HIV-infected subjects as due to AIDS; however, this is
unlikely because classification of a death as due to AIDS
requires the presence of an AIDS-defining condition.
Liver diseases were the second cause of death in per-
sons living with HIV, which may be explained by coin-
fections with hepatitis B or C viruses, which share the
same sexual and parenteral mechanisms of transmission
as HIV, and by high levels of alcohol and drug use [26].
Of note is the high mortality associated with drug over-
dose or addiction [14,27], which could have previously
been partly masked by AIDS mortality and may only
now be coming to the fore due to improved survival in
HIV infection [4]. Excess cardiovascular mortality has
been related with some antiviral treatments [28], but
recent studies suggest an effect of the infection itself
[29]. Non-AIDS-defining cancers play a larger than
expected role as a cause of death in HIV-infected per-
sons [30], comprising 8% of deaths, a percentage close
to that found in other studies [31]. Among the explana-
tions offered for these types of cancer are HIV-induced
immunosuppression and the high frequency of
unhealthy habits like smoking [32]. Combined antiretro-
viral treatments may be reducing the mortality of both
AIDS-defining and non-AIDS-defining cancers [33]. In
agreement with other studies, we found a high mortality
from suicide among HIV-infected persons [34]. Despite
advances in the treatment of HIV infection and
increased survival in these patients, their mortality rates
remain higher than those in the general population [35].
Only by investigating the factors that determine these
causes of death will we be able to act on them.
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Page 4 of 8Table 3 Standardized mortality ratio by cause of death, injecting-drug status and sex in HIV-infected subjects
compared with persons in the general population not diagnosed with HIV infection; Navarre, Spain, 1999-2006
Observed deaths Expected deaths Standardized mortality ratio (95% CI)
All HIV-infected subjects
All-cause deaths 210 15.0 14.0 (12.2-16.1)
Non-AIDS deaths 104 15.0 6.9 (5.7-8.5)
Liver disease 36 0.5 69.0 (48.1-78.6)
Non-AIDS defining cancer 17 5.4 3.2 (1.8-5.1)
Drug overdoses or addiction 23 0.5 46.0 (29.2-69.0)
Cardiovascular disease 8 2.6 3.1 (1.3-6.1)
Suicide 7 0.7 9.6 (3.8-19.7)
Other external causes 4 3.0 1.3 (0.4-3.4)
All other causes 9 1.8 5.1 (2.3-9.7)
Injecting drug users
All-cause deaths 162 9.1 17.7 (15.2-20.8)
Non-AIDS deaths 88 9.1 9.6 (7.7-12.0)
Liver disease 30 0.3 96.6 (65.2-138.1)
Non-AIDS defining cancer 12 3.0 4.0 (2.1-7.0)
Drug overdoses or addiction 23 0.4 63.4 (40.2-95.1)
Cardiovascular disease 6 1.5 4.0 (1.5-8.6)
Suicide 5 0.5 10.8 (3.5-25.3)
Other external causes 4 2.0 2.0 (0.5-5.1)
All other causes 8 1.1 7.3 (3.2-14.4)
Non-injecting drug users
All-cause deaths 48 5.9 8.2 (6.0-11.0)
Non-AIDS deaths 16 5.9 2.7 (1.6-4.4)
Liver disease 6 0.2 28.4 (10.4-62.0)
Non-AIDS defining cancer 5 2.3 2.1 (0.7-5.0)
Drug overdoses or addiction 0 0.1 0
Cardiovascular disease 2 1.1 1.8 (0.2-6.6)
Suicide 2 0.3 7.4 (0.89-26.6)
Other external causes 0 1.0 0
All other causes 1 0.7 1.5 (0.04-8.2)
Male
All-cause deaths 162 12.5 12.9 (11.0-15.1)
Non-AIDS deaths 78 12.5 6.2 (4.9-7.9)
Liver disease 25 0.5 54.1 (35.0-80.1)
Non-AIDS defining cancer 13 4.1 3.1 (1.7-5.4)
Drug overdoses or addiction 20 0.5 43.3 (26.5-66.7)
Cardiovascular disease 6 2.4 2.5 (0.9-5.6)
Suicide 4 0.5 7.3 (2.0-18.7)
Other external causes 3 2.7 1.1 (0.2-3.3)
All other causes 7 1.4 5.0 (2.0-10.2)
Female
All-cause deaths 48 2.5 19.5 (14.2-26.1)
Non-AIDS deaths 26 2.5 10.6 (6.9-15.5)
Liver disease 11 0.1 183.3 (91.5-328.1)
Non-AIDS defining cancer 4 1.2 3.3 (0.9-8.3)
Drug overdoses or addiction 3 0.04 78.5 (16.2-229.3)
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ity by causes of death in HIV-infected people, including
cases and events that could be not detected in clinical
cohorts. Therefore, we have not included some baseline
variables such as antiretroviral treatments, viral load and
CD4 cell count which are relevant from a clinical
perspective.
Losses to follow-up are one of the main sources of
bias in follow-up studies. We tried to reduce such losses
in our study by searching for subjects in a variety of
information sources in order to detect or rule out their
death. AIDS-related deaths included those due to AIDS-
defining conditions, including opportunistic infections,
some cancers and tuberculosis, which are the most fre-
quent but not exclusive causes of death in persons with
HIV-infection. We partly overcame this problem of
comparability with the general population by not
including deaths from liver disease in HIV-infected per-
sons as deaths from AIDS. However, it was not possible
to compare persons with HIV and the general popula-
tion with respect to deaths from AIDS-defining diseases.
Our results are marked by the epidemiological pattern
in the study area, which is characterized by a predomi-
nance of HIV infections acquired in relation with inject-
ing drug use [17]. Thus, they may not be generalized to
other areas with a different epidemiological pattern.
Conclusions
In the era of combined antiretroviral treatments, we still
find considerable excess mortality in persons living with
HIV. Since these treatments were introduced, advances
have continued to be made in reducing this excess mor-
tality, especially in persons without a history of injecting
drug use. Further reduction will require improvements
Table 3 Standardized mortality ratio by cause of death, injecting-drug status and sex in HIV-infected subjects com-
pared with persons in the general population not diagnosed with HIV infection; Navarre, Spain, 1999-2006 (Continued)
Cardiovascular disease 2 0.2 8.0 (1.0-29.0)
Suicide 3 0.2 16.4 (3.4-47.8)
Other external causes 1 0.3 2.9 (0.1-16.4)
All other causes 2 0.4 5.5 (0.7-20.0)
Table 4 Comparison of mortality by cause of death in HIV-infected cohort in the periods 1999-2002 and 2003-2006;
Navarre, Spain.
Period 1999-2002 Period 2003-2006
Cases Rate per 1000 PY Cases Rate per 1000 PY Hazard ratio* (95% CI) P-value
All HIV-infected subjects
All-cause deaths 115 32.6 95 26.5 0.72 (0.54-0.96) 0.024
AIDS deaths 62 17.6 44 12.3 0.63 (0.42-0.95) 0.026
Non-AIDS related deaths 53 15.0 51 14.2 0.82 (0.54-1.23) 0.325
Liver disease 14 4.0 22 6.1 1.34 (0.66-2.72) 0.420
Non-AIDS defining cancer 10 2.8 7 2.0 0.47 (0.17-1.30) 0.145
Drug overdoses or addiction 14 4.0 9 2.5 0.63 (0.26-1.53) 0.307
Cardiovascular disease 3 0.9 5 1.4 1.12 (0.25-5.06) 0.880
Suicide 3 0.9 4 1.1 1.26 (0.26-6.04) 0.776
Other external causes 3 0.9 1 0.3 0.21 (0.02-2.16) 0.190
All other causes 6 1.7 3 0.9 0.58 (0.13-2.50) 0.461
Injecting drug users
All-cause deaths 85 33.5 77 33.5 0.85 (0.60-1.19) 0.336
AIDS deaths 43 16.9 31 13.5 0.68 (0.41-1.13) 0.132
Non-AIDS related deaths 42 16.5 46 20.2 1.02 (0.65-1.61) 0.933
Non-injecting drug users
All-cause deaths 30 30.4 18 14.0 0.44 (0.24-0.79) 0.007
AIDS deaths 19 19.3 13 10.1 0.49 (0.24-1.02) 0.057
Non-AIDS related deaths 11 11.2 5 3.9 0.33 (0.11-0.96) 0.041
PY, person-years. CI, confidence interval.
*Hazard ratio obtained in Cox regression models with age as underlying time variable and adjusted for sex, country of origin (Spain or others) and injecting
drug use.
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ment as well as special emphasis on measures to prevent
cancer, cardiovascular disease, and the whole range of
problems related with injecting drug use.
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